OncoSil Medical Says Encouraging Pancreatic Cancer Therapy Data to Be Presented at Chicago Conference; Shares Gain 13%

MT Newswires Live05-22 09:59

OncoSil Medical (ASX:OSL) said data highlighting the "excellent safety" of its OncoSil device for the treatment of pancreatic cancer will be presented at an American Society of Clinical Oncology conference in Chicago on May 30, according to a Friday filing with the Australian bourse.

The data to be presented shows "a high percentage of surgical resection rates" achieved in locally advanced pancreatic cancer patients who were deemed unresectable at diagnosis, per the filing.

The treatment with the OncoSil device showed a favorable safety profile and a median progression-free survival of 8.5 months, the company said.

Shares of OncoSil Medical advanced nearly 13% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637361551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 09:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637361551","market":"hk","top_or_hot":-1,"title":"OncoSil Medical Says Encouraging Pancreatic Cancer Therapy Data to Be Presented at Chicago Conference; Shares Gain 13%","media":"MT Newswires Live","content":"<html><body><p> OncoSil Medical (ASX:OSL) said data highlighting the \"excellent safety\" of its OncoSil device for the treatment of pancreatic cancer will be presented at an American Society of Clinical Oncology conference in Chicago on May 30, according to a Friday filing with the Australian bourse.</p><p>The data to be presented shows \"a high percentage of surgical resection rates\" achieved in locally advanced pancreatic cancer patients who were deemed unresectable at diagnosis, per the filing.</p><p>The treatment with the OncoSil device showed a favorable safety profile and a median progression-free survival of 8.5 months, the company said.</p><p>Shares of OncoSil Medical advanced nearly 13% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSil Medical Says Encouraging Pancreatic Cancer Therapy Data to Be Presented at Chicago Conference; Shares Gain 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSil Medical Says Encouraging Pancreatic Cancer Therapy Data to Be Presented at Chicago Conference; Shares Gain 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-22 09:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OncoSil Medical (ASX:OSL) said data highlighting the \"excellent safety\" of its OncoSil device for the treatment of pancreatic cancer will be presented at an American Society of Clinical Oncology conference in Chicago on May 30, according to a Friday filing with the Australian bourse.</p><p>The data to be presented shows \"a high percentage of surgical resection rates\" achieved in locally advanced pancreatic cancer patients who were deemed unresectable at diagnosis, per the filing.</p><p>The treatment with the OncoSil device showed a favorable safety profile and a median progression-free survival of 8.5 months, the company said.</p><p>Shares of OncoSil Medical advanced nearly 13% in recent Friday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSL.AU","symbol_name":"ONCOSIL MEDICAL LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2637361551","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637361551","pubTimestamp":1779415192,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OncoSil Medical  said data highlighting the \"excellent safety\" of its OncoSil device for the treatment of pancreatic cancer will be presented at an American Society of Clinical Oncology conference in Chicago on May 30, according to a Friday filing with the Australian bourse.The data to be presented shows \"a high percentage of surgical resection rates\" achieved in locally advanced pancreatic cancer patients who were deemed unresectable at diagnosis, per the filing.The treatment with the OncoSil device showed a favorable safety profile and a median progression-free survival of 8.5 months, the company said.Shares of OncoSil Medical advanced nearly 13% in recent Friday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OSL.AU":"ONCOSIL MEDICAL LTD","BK7508":"医药生物股","BK7048":"生命科学工具和服务"},"translate_title":"OncoSil Medical表示鼓励在芝加哥会议上展示胰腺癌治疗数据；股价上涨13%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSL.AU":1},"content_text":"OncoSil Medical (ASX:OSL) said data highlighting the \"excellent safety\" of its OncoSil device for the treatment of pancreatic cancer will be presented at an American Society of Clinical Oncology conference in Chicago on May 30, according to a Friday filing with the Australian bourse.The data to be presented shows \"a high percentage of surgical resection rates\" achieved in locally advanced pancreatic cancer patients who were deemed unresectable at diagnosis, per the filing.The treatment with the OncoSil device showed a favorable safety profile and a median progression-free survival of 8.5 months, the company said.Shares of OncoSil Medical advanced nearly 13% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637361551","isCrawlerRequest":true}